Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Daiichi Sankyo Company, Limited
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Valuation == '''Market Cap''' To estimate the value of Daiichi Sankyo it is helpful to consider the Market Capitalisation, which is a calculation of the company's total value based on its current stock price and the number of outstanding shares: '''Market Cap = Stock Price * Number of Outstanding Shares''' As of 28th July 2023, Daiichi Sankyo's stock price is listed as Β₯4,095, with 1.92B outstanding shares. Thus the Market Capitalisation of Daiichi Sankyo is approximately '''Β₯7.9T''' or '''$56.9B''', which represents the total market value of the company's equity outstanding and provides an indication of the company's current market value. Comparing Daiichi Sankyo's Market Cap with that of its peers can provide insights into how the market perceives the company's value relative to its competitors (As of July 2023): # Takeda Pharmaceutical Co Ltd, Market Cap '''-''' $49.8B -Japanese company specialising in gastroenterology, oncology, and neuroscience. # Astellas Pharma Inc, Market Cap - $27.1B -Japanese pharmaceutical company which competes with Daiichi Sankyo in oncology and other therapeutic areas. # Chugai Pharmaceutical Co Ltd, Market Cap - $49.1B -Biopharmaceutical company competing with Daiichi Sankyo in Japan and globally in oncology and immunology therapies. # Merck & Co Inc, Market Cap - $267.1B -Global pharmaceutical company focused on oncology, vaccines, infectious diseases, and cardiovascular medications. # Pfizer Inc, Market Cap - $204.4B -Global pharmaceutical company engaged in prescription medications, vaccines, and consumer health products. # Novartis AG, Market Cap - $235.5B -Multinational pharmaceutical company competing with Daiichi Sankyo in cardiovascular drugs, oncology treatments, and immunology therapies. # AstraZeneca PLC, Market Cap - $169.1B -Pharmaceutical company focused on medications for respiratory, cardiovascular, oncology, and other therapeutic areas, competes with Daiichi Sankyo in cardiovascular drugs and oncology treatments. # GlaxoSmithKline (GSK), Market Cap - $57.3B -Multinational pharmaceutical company developing pharmaceutical products, vaccines, and consumer healthcare products.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)